Business context and reporting period
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing CNS and pain treatments. This Form 10-K covers the fiscal year ended December 31, 2016; it was signed March 7, 2017. The company had no approved products and generated no revenue.
Lead programs were AXS-05, in Phase 3 for treatment-resistant depression (TRD), and AXS-02, in Phase 3 for complex regional pain syndrome (CRPS) and knee osteoarthritis pain associated with bone marrow lesions (BMLs). The filing also describes planned studies in Alzheimer’s agitation and chronic low back pain associated with Modic changes.
Financial performance and liquidity
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $21.2 million | $6.8 million |
| General and administrative expense | $6.3 million | $2.4 million |
| Total operating expenses | $27.5 million | $9.2 million |
| Net loss | $27.2 million | $12.2 million |
| Basic and diluted loss per share | $1.42 | $1.02 |
| Cash used in operating activities | $21.3 million | $7.4 million |
| Cash at year-end | $36.6 million | $48.0 million |
Losses widened as late-stage clinical programs expanded. No revenue means operating margins are not meaningful. Cash and cash equivalents were not separately materialized beyond reported cash; the filing states there were no cash equivalents at year-end. Management estimated available cash would fund anticipated operating needs through the first quarter of 2018, subject to assumptions and trial costs.
At December 31, 2016, total assets were $38.2 million, current liabilities $7.2 million, and total liabilities $16.6 million. The company had a $10.0 million SVB term loan funded, with $9.7 million reported as long-term debt net of discount and $0.3 million current. Up to $10.0 million of additional advances were available only upon specified clinical and financing milestones. The loan bears interest at 4.5% above prime, includes an 8.5% final payment fee, matures in November 2020, and is secured by company assets other than intellectual property.
Material changes and notable developments
- R&D expense rose by $14.4 million year over year, mainly reflecting the CREATE-1, STRIDE-1, and COAST-1 trials, alongside increased personnel and stock compensation costs. G&A increased by $3.9 million, principally from public-company and personnel costs.
- Operating cash use increased by $13.8 million year over year. Cash declined by $11.4 million during 2016 despite $10.0 million in loan proceeds.
- COAST-1 enrollment screening was paused pending an interim analysis of approximately 60 participants to reassess sample-size assumptions; management anticipated results in the third quarter of 2017 and planned to resume screening after readouts from other Phase 3 trials.
- The company filed an effective $150 million shelf registration statement in December 2016, enabling potential future securities offerings; no amount under the shelf was reported as issued in this filing.
- Management disclosed a prior material weakness involving review of non-routine complex transactions and a restatement of 2015 and first-quarter 2016 financial statements to record a non-cash premium to additional paid-in capital. Management stated the weakness was remediated by year-end 2016. The independent auditor audited the financial statements but did not audit internal control effectiveness.
Outlook, risks, contingencies, and unusual items
- Management expected R&D and G&A expenses to increase modestly in 2017 and anticipated continued substantial losses. It provided no revenue or profitability guidance and expected no near-term product revenue.
- Anticipated milestones included STRIDE-1 TRD top-line results in Q1 2018; CREATE-1 interim efficacy results in Q4 2017; and COAST-1 interim analysis results in Q3 2017. The planned AXS-05 Alzheimer’s agitation Phase 2/3 trial was expected to start in Q2 2017. AXS-02’s planned Phase 3 low-back-pain trial was contingent on available resources.
- Principal risks include clinical failure or delay, patient enrollment and safety issues, FDA reliance on the 505(b)(2) pathway, manufacturing and commercialization readiness, future financing needs, reimbursement and pricing, and competition. The company cautioned that interim results may not predict final trial outcomes.
- Grünenthal had petitioned for post-grant review of a U.S. patent covering oral zoledronic acid for CRPS; Axsome said it intended to oppose the petition. The outcome and potential impact on AXS-02 patent protection were uncertain.
- AXS-02 and AXS-05 licenses are held through Antecip, an entity owned by the CEO and board chairman. The agreements provide for royalties on future net sales and create disclosed related-party and potential-conflict considerations.
- Axsome reported no material pending legal proceedings. The filing notes its cash was largely held at one financial institution in excess of FDIC insurance limits.
Most important facts for investors to verify
- Current cash runway and financing plans versus actual trial spending, including whether milestone conditions for additional SVB advances are met.
- Clinical-trial enrollment, interim-analysis results, final endpoints, safety findings, and whether timelines have changed.
- Status and outcome of the patent review petition and the scope and enforceability of AXS-02 and AXS-05 intellectual-property rights.
- Progress in remediating financial-reporting controls and any subsequent restatements or control deficiencies.
- Terms and dilution impact of any future financing under the shelf registration statement, plus the loan’s covenants, fees, and repayment obligations.
- Commercial readiness, manufacturing capacity, FDA requirements, and expected payer coverage and reimbursement if any candidate is approved.